

RE: SMEInst-01-2016-2017: Open Disruption Innovative Scheme

4 August, 2017

Dear Colleagues:

I am pleased to offer our support for the Medilync's Insulync submission to the upcoming Open Disruption Innovation Scheme.

We believe strongly that high quality, logical, patient-centric industrial design is critical to the future of medical device innovation and development. Based on our initial evaluation of technologies from Medilync, we believe that your company shares this vision and has developed technology that has enormous promise to improve day-to-day adherence and care.

As director of a unit that focuses on the nexus of medical devices with consumer electronics in the field of diabetes and human movement, we see the day-to-day challenges that our patients face. This innovation scheme in general and this proposal specifically is directly linked to our practice and patients.

We wish you the best on this proposal and endorse it with enthusiasm. Please keep us up to date on its progress.

Yours very truly,



David G. Armstrong, DPM, MD, PhD

Professor of Surgery

Director, Southwestern Academic Limb Salvage Alliance (SALSA)

Keck School of Medicine, University of Southern California

